While there are no studies proving their value in ARVC patients, there are many trials demonstrating the critical role of ACE inhibitor therapy in patients with ischemic and non-ischemic forms of dilated cardiomyopathy. The gene discussed is ACE; the disease is arrhythmogenic right ventricular cardiomyopathy.